Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 6;157(9):611-20.
doi: 10.7326/0003-4819-157-9-201211060-00005.

Rescreening of persons with a negative colonoscopy result: results from a microsimulation model

Affiliations

Rescreening of persons with a negative colonoscopy result: results from a microsimulation model

Amy B Knudsen et al. Ann Intern Med. .

Abstract

Background: Persons with a negative result on screening colonoscopy are recommended to repeat the procedure in 10 years.

Objective: To assess the effectiveness and costs of colonoscopy versus other rescreening strategies after an initial negative colonoscopy result.

Design: Microsimulation model.

Data sources: Literature and data from the Surveillance, Epidemiology, and End Results program.

Target population: Persons aged 50 years who had no adenomas or cancer detected on screening colonoscopy.

Time horizon: Lifetime.

Perspective: Societal.

Intervention: No further screening or rescreening starting at age 60 years with colonoscopy every 10 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemical testing (FIT), or computed tomographic colonography (CTC) every 5 years.

Outcome measures: Lifetime cases of colorectal cancer, life expectancy, and lifetime costs per 1000 persons, assuming either perfect or imperfect adherence.

Results of base-case analysis: Rescreening with any method substantially reduced the risk for colorectal cancer compared with no further screening (range, 7.7 to 12.6 lifetime cases per 1000 persons [perfect adherence] and 17.7 to 20.9 lifetime cases per 1000 persons [imperfect adherence] vs. 31.3 lifetime cases per 1000 persons with no further screening). In both adherence scenarios, the differences in life-years across rescreening strategies were small (range, 30 893 to 30 902 life-years per 1000 persons [perfect adherence] vs. 30 865 to 30 869 life-years per 1000 persons [imperfect adherence]). Rescreening with HSFOBT, FIT, or CTC had fewer complications and was less costly than continuing colonoscopy.

Results of sensitivity analysis: Results were sensitive to test-specific adherence rates.

Limitation: Data on adherence to rescreening were limited.

Conclusion: Compared with the currently recommended strategy of continuing colonoscopy every 10 years after an initial negative examination, rescreening at age 60 years with annual HSFOBT, annual FIT, or CTC every 5 years provides approximately the same benefit in life-years with fewer complications at a lower cost. Therefore, it is reasonable to use other methods to rescreen persons with negative colonoscopy results.

Primary funding source: National Cancer Institute.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of the SimCRC natural history model (solid lines) with the effect of screening noted (dashed lines). Individuals enter the model at birth free of colorectal cancer and adenomas. Over time they are at risk of forming one or more adenomas, each of which has the chance of growing in size and progressing to preclinical (ie, undiagnosed) and ultimately, clinical (ie, diagnosed), colorectal cancer. Screening has the ability to interrupt the natural history by detecting preclinical cancers before they progress to a more advanced stage, and detecting adenomas for removal, thereby preventing their potential to transition to colorectal cancer.
Figure 2
Figure 2
Life-years (A) and lifetime costs (B) per 1000 50-year-old individuals with a negative screening colonoscopy with imperfect adherence (see Appendix Table 1): sensitivity analysis on adherence rates. COL = colonoscopy; CTC = computed tomographic colonography with ≥6mm threshold for colonoscopy referral; HSFOBT = highly-sensitive guaiac fecal occult blood test; FIT = fecal immunochemical test; NFS = no further screening.

Comment in

Similar articles

Cited by

References

    1. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603–7. - PubMed
    1. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624–33. - PubMed
    1. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345–57. - PMC - PubMed
    1. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol. 2004;39(9):846–51. - PubMed
    1. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434–7. - PubMed

Publication types

MeSH terms